Home>Topics>Stocks>Teva Pharmaceutical Industries

Teva Pharmaceutical Industries TEVA

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Teva discloses 1.35 pct stake in target Mylan

      Headlines

      Wed, 27 May 2015

      May 27 (Reuters) - Teva Pharmaceutical Industries Ltd disclosed a 1.35 percent interest in Mylan NV , saying the purchase underscored its commitment to buy Mylan as soon as possible.

    2. Endo Builds Generic Business Through Acquisition of Par Pharmaceuticals

      Commentary

      Sun, 17 May 2015

      growth prospects, we still think Par appears considerably disadvantaged, even following a combination with Endo (Peers such as Teva , Mylan, Dr. Reddy’s, and Hikma are more vertically integrated and run lower cost operations). Endo's management has

    3. UPDATE 2-Top California court revives Cipro antitrust case

      Headlines

      Thu, 7 May 2015

      May 7 (Reuters) - California's highest court on Thursday revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of...

    4. Top California court revives Cipro antitrust case

      Headlines

      Thu, 7 May 2015

      May 7 (Reuters) - California's highest court has revived an antitrust class action accusing a drugmaker since acquired by Teva Pharmaceutical Industries Ltd of keeping a generic version of Bayer AG's...

    5. Mylan Posts Decent First Quarter as M&A Situation Remains Uncertain

      Commentary

      Wed, 6 May 2015

      challenges. Mylan remains persistent in its pursuit of Perrigo, but we still think the situation remains highly uncertain thanks to Teva ’s own offer $82 per share (50% cash/50% stock) for Mylan. As we have previously stated, we think Perrigo’s over

    6. Momenta Posts In-Line Quarter; Raising Our Fair Value Estimate on Generic Copaxone Approval

      Commentary

      Fri, 1 May 2015

      We've adjusted our revenue and profit forecast for the company as the sole generic approval for the time being, but with Teva ’s ability to continually shift more patients into a new three-times-per-week formulation until our estimate of a generic

    7. UPDATE 2- Teva lifts 2015 earnings forecast as pursues Mylan bid

      Headlines

      Thu, 30 Apr 2015

      * Teva shares down 1.2 pct in New York (Adds comments on Mylan, Copaxone, analyst, shares)

    8. BRIEF- Teva Pharm on protecting Copaxone 40 mg patent

      Headlines

      Thu, 30 Apr 2015

      * Confident in our ability to defend patent on 40 mg Copaxone Further company coverage: (Reporting By Steven Scheer and Tova Cohen)

    9. BRIEF- Teva CEO on Mylan bid

      Headlines

      Thu, 30 Apr 2015

      April 30 (Reuters) - Teva Pharmaceutical Industries TEVA .N> CEO Erez Vigodman says:

    10. Teva Pharm Q1 profit beats forecasts, raises 2015 outlook

      Headlines

      Thu, 30 Apr 2015

      TEL AVIV, April 30 (Reuters) - Teva Pharmaceutical Industries , which is seeking to acquire rival Mylan Inc for over $40 billion, posted higher first quarter net profit that beat analysts' estimates and raised its full year outlook.

    « Prev12345Next »
    Content Partners